Eliana Merle
Stock Analyst at UBS
(2.16)
# 1,506
Out of 4,412 analysts
45
Total ratings
36.11%
Success rate
-0.57%
Average return
Main Sectors:
Top Industries:
22 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KOD Kodiak Sciences | Maintains: Neutral | $3 → $5 | $3.28 | +52.44% | 3 | Apr 4, 2024 | |
| TERN Terns Pharmaceuticals | Maintains: Buy | $19 → $18 | $4.91 | +266.60% | 2 | Mar 27, 2024 | |
| BNTX BioNTech SE | Maintains: Neutral | $110 → $101 | $87.21 | +15.81% | 3 | Mar 27, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $337 → $410 | $193.33 | +112.07% | 2 | Mar 15, 2024 | |
| AKRO Akero Therapeutics | Maintains: Buy | $39 → $42 | $19.74 | +112.77% | 3 | Mar 5, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $87 → $89 | $49.86 | +78.50% | 4 | Mar 4, 2024 | |
| RAPT RAPT Therapeutics | Downgrades: Neutral | $61 → $10 | $8.10 | +23.46% | 1 | Feb 22, 2024 | |
| RVMD Revolution Medicines | Initiates: Buy | $40 | $35.96 | +11.23% | 1 | Dec 20, 2023 | |
| ANAB AnaptysBio | Maintains: Neutral | $28 → $21 | $21.00 | - | 3 | Nov 2, 2023 | |
| ETNB 89bio | Maintains: Buy | $36 → $25 | $8.26 | +202.66% | 2 | Oct 12, 2023 | |
| MRNA Moderna | Upgrades: Buy | $221 → $191 | $107.97 | +76.90% | 2 | Jun 26, 2023 | |
| QURE uniQure | Maintains: Buy | $45 → $42 | $4.53 | +827.15% | 4 | May 19, 2023 | |
| CVAC CureVac | Upgrades: Buy | $18 | $2.33 | +672.53% | 1 | Jan 19, 2023 | |
| GOSS Gossamer Bio | Maintains: Buy | $19 → $8 | $0.67 | +1,097.60% | 2 | Dec 7, 2022 | |
| GLUE Monte Rosa Therapeutics | Initiates: Buy | $22 | $5.33 | +312.76% | 1 | Oct 13, 2022 | |
| RGNX REGENXBIO | Maintains: Buy | $51 → $47 | $16.19 | +190.30% | 1 | Jun 23, 2022 | |
| FOLD Amicus Therapeutics | Initiates: Buy | n/a | $10.28 | - | 2 | May 21, 2021 | |
| KYMR Kymera Therapeutics | Initiates: Buy | n/a | $33.37 | - | 1 | May 21, 2021 | |
| ZNTL Zentalis Pharmaceuticals | Initiates: Buy | n/a | $11.06 | - | 2 | May 21, 2021 | |
| ARVN Arvinas | Initiates: Buy | n/a | $32.37 | - | 2 | May 21, 2021 | |
| BBIO BridgeBio Pharma | Initiates: Buy | n/a | $24.88 | - | 1 | May 21, 2021 | |
| GLPG Galapagos NV | Maintains: Neutral | n/a | $28.76 | - | 2 | Aug 19, 2020 |
Kodiak Sciences
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $3.28
Upside: +52.44%
Terns Pharmaceuticals
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $4.91
Upside: +266.60%
BioNTech SE
Mar 27, 2024
Maintains: Neutral
Price Target: $110 → $101
Current: $87.21
Upside: +15.81%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $337 → $410
Current: $193.33
Upside: +112.07%
Akero Therapeutics
Mar 5, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $19.74
Upside: +112.77%
Apellis Pharmaceuticals
Mar 4, 2024
Maintains: Buy
Price Target: $87 → $89
Current: $49.86
Upside: +78.50%
RAPT Therapeutics
Feb 22, 2024
Downgrades: Neutral
Price Target: $61 → $10
Current: $8.10
Upside: +23.46%
Revolution Medicines
Dec 20, 2023
Initiates: Buy
Price Target: $40
Current: $35.96
Upside: +11.23%
AnaptysBio
Nov 2, 2023
Maintains: Neutral
Price Target: $28 → $21
Current: $21.00
Upside: -
89bio
Oct 12, 2023
Maintains: Buy
Price Target: $36 → $25
Current: $8.26
Upside: +202.66%
Moderna
Jun 26, 2023
Upgrades: Buy
Price Target: $221 → $191
Current: $107.97
Upside: +76.90%
uniQure
May 19, 2023
Maintains: Buy
Price Target: $45 → $42
Current: $4.53
Upside: +827.15%
CureVac
Jan 19, 2023
Upgrades: Buy
Price Target: $18
Current: $2.33
Upside: +672.53%
Gossamer Bio
Dec 7, 2022
Maintains: Buy
Price Target: $19 → $8
Current: $0.67
Upside: +1,097.60%
Monte Rosa Therapeutics
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $5.33
Upside: +312.76%
REGENXBIO
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $16.19
Upside: +190.30%
Amicus Therapeutics
May 21, 2021
Initiates: Buy
Price Target: n/a
Current: $10.28
Upside: -
Kymera Therapeutics
May 21, 2021
Initiates: Buy
Price Target: n/a
Current: $33.37
Upside: -
Zentalis Pharmaceuticals
May 21, 2021
Initiates: Buy
Price Target: n/a
Current: $11.06
Upside: -
Arvinas
May 21, 2021
Initiates: Buy
Price Target: n/a
Current: $32.37
Upside: -
BridgeBio Pharma
May 21, 2021
Initiates: Buy
Price Target: n/a
Current: $24.88
Upside: -
Galapagos NV
Aug 19, 2020
Maintains: Neutral
Price Target: n/a
Current: $28.76
Upside: -